Atrium Therapeutics Inc.

RNA | NASDAQ

Price Alert Chart Builder DCF Calculator

$9.19

+$0.24 (+2.68%)

Sep 21, 2026, 12:07 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+2.68%

(1D)

Rating

Updated: Aug 20, 2026

17.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $157.12M

1D Range

8.94 9.34

52W Range

8.66 16.77

Valuation (TTM)

PE -2.32

PB 0.71

EV/EBITDA 1.26

Valuation (NTM)

Forward PE N/A

Forward PEG -0.04

Price Target $25

Cash Flow

FCF Yield -37.5%

SBC Adj. FCF Yield -39.8%

SBC Impact -6.2%

Margins

Gross Margin 97.9%

Operating Margin -374.2%

FCF Margin -244.0%

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y N/A | N/A

FCF 3Y | 5Y N/A | N/A

Returns

ROA -33.2%

ROE -42.9%

ROIC -38.4%

Financial Health

Net Cash

$262.53M

Current Ratio 8.73

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the hea...

Sector Healthcare

Industry Biotechnology

Employees 511

IPO Date Feb 26, 2026

Website www.atriumtherapeutics.com

Fiscal Year n/a

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 12, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Hold

Price Target

$25

Upside

+172.03%

Buy (2)

Hold (8)

Sell (0)

Analyst Details ➞